mutations and sophisticated kar yotype. It follows a linear evolution in the CLL clone through the recurrent acquisition of CDKN2AGenetic susceptibility mechanisms. Most susceptibility loci map to non-coding locations of your genome, are mainly situated in active promoters or enhancers, and modify the binding websites of a number of transcription f